2 Under-the-Radar Biotech Stocks Set to Boom in 2026
Biotech headwinds are driving double-digit revenue growth and profitability for these two mid-caps.
| Ticker |
CPRX
|
| CIK | 0001369568 |
| SIC | 2834 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Pharmaceutical Preparations |
| Address | 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES, FL, 33134 |
| Website | catalystpharma.com |
| Phone | (305) 529-2522 |
| CEO | Patrick J. McEnany |
| Employees | 80 |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
2 Under-the-Radar Biotech Stocks Set to Boom in 2026Biotech headwinds are driving double-digit revenue growth and profitability for these two mid-caps. Catalyst Pharmaceuticals, Inc. (CPRX): A Bull Case TheoryWe came across a bullish thesis on Catalyst Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on CPRX. Catalyst Pharmaceuticals, Inc.’s share was trading at $22.96 as of January 15th. CPRX’s trailing and forward P/E were 13.43 and 10.34 respectively according to Yahoo Finance. Catalyst Pharmaceuticals (CPRX) is positioned as a leading […] Jim Cramer on Catalyst Pharmaceuticals: “It’s a Very Inexpensive Stock”Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is one of the stocks on Jim Cramer’s radar recently. During the lightning round, a caller asked if they should buy more, hold, or sell their position in the stock, and here’s what Cramer had to say in response: “I like Catalyst Pharmaceuticals. It actually has, by the way, real earnings, […] Does Forbes’ Small-Cap Honor for Sales Growth Reshape the Bull Case For Catalyst Pharmaceuticals (CPRX)?Catalyst Pharmaceuticals recently announced that it was ranked 11th on Forbes’ 2026 list of America’s Most Successful Small-Cap Companies, recognizing its sales growth and financial performance as a rare disease–focused biopharmaceutical firm. This recognition not only highlights Catalyst’s commercial execution but also spotlights its positioning in the competitive small-cap biotech space focused on rare conditions. We’ll now examine how this Forbes recognition for sales growth and execution... CPRX or DSNKY: Which Is the Better Value Stock Right Now?CPRX vs. DSNKY: Which Stock Is the Better Value Option? |